The filings come in advance of a merger with a rival for $300 million — a small fraction of the billions Zymergen once hoped to generate.
Ginkgo does not make products for itself but uses genetic engineering to make bacteria for its customers to use in industrial processes.
On Dec. 15, Zymerge’s board looked at various strategic initiatives, including a potential carve-out of the company’s automation business, either with a financing and separation or as a sale. By the end of the month, Zymergen’s board considered three options: sell the company, carve out the automation business, possibly in combination with other Zymergen businesses, or continue to operate as a standalone company through a private investment in public equity, or PIPE, transaction or an at-the-market, or ATM, equity offering.
It was those same costs, and the ballooning size of Zymergen's workforce, that co-founders of the now-nine-year-old company believed was necessary to meet what they forecast to be unparalleled demand for environmentally friendly, biological solutions that would supersede the use of fossil fuels in many products.
With a PIPE offering, the company approached 10 financial parties, but all of them cited Zymergen’s cash burn as one of the reasons not to participate.
Argentina Últimas Noticias, Argentina Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
San Francisco Offers No Escape From Brutal HeatWith most heat waves, San Francisco becomes the place to escape to. But that’s not the case this time.
Leer más »
Official records fall in SF Bay Area, more to come on hotter TuesdayCalifornia's San Francisco Bay Area baked amid dangerous heat over the Labor Day weekend, breaking a slew of temperature records at official National Weather Service gauges.
Leer más »
Dodgers vs. San Francisco Giants: How to watch, streaming options and start timesHere's how to watch on TV and stream the three-game series between the Dodgers and the San Francisco Giants at Dodger Stadium, starting Monday.
Leer más »
Florida sues FDA over 'delay' of low-cost drug importationsFlorida has sued federal health officials, accusing them of stalling the state's plan to import lower-cost prescription drugs from Canada
Leer más »